{"filing":{"accession_number":"0001725160-26-000061","cik":"0001725160","ticker":"ZNTL","company_name":"Zentalis Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"zntl-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/zntl-20260806.htm"},"events":[{"id":25957,"run_id":23571,"accession_number":"0001725160-26-000061","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Zentalis Pharmaceuticals reported second quarter 2026 financial results and business updates, including cash position of $174.6 million, R\u0026D expenses of $35.2 million, and G\u0026A expenses of $9.2 million, along with material clinical milestones including DENALI enrollment completion, FDA Type D meeting alignment, and ASPENOVA Phase 3 first patient dosed.","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26908,"accession_number":"0001725160-26-000061","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results including cash position ($174.6 million), R\u0026D expenses ($35.2 million), and G\u0026A expenses ($9.2 million), along with business updates on clinical trial progress. The Item 2.02 classification and attached press release (Exhibit 99.1) titled \"Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates\" confirm this is a standard earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:02.084003+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26909,"accession_number":"0001725160-26-000061","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a Corporate Presentation (Exhibit 99.2) to be presented at investor conferences, but the substantive content is driven by Exhibit 99.1, which is a formal earnings release announcing \"Second Quarter 2026 Financial Results and Business Updates.\" The release discloses Q2 2026 financial results (R\u0026D expenses of $35.2M, G\u0026A of $9.2M, cash position of $174.6M) and material clinical/regulatory milestones (DENALI enrollment completion, FDA Type D meeting alignment, ASPENOVA Phase 3 first patient dosed). This is a classic earnings release with financial results and material business updates, even though technically filed under Item 7.01 rather than Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:02.084003+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26908,"accession_number":"0001725160-26-000061","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results including cash position ($174.6 million), R\u0026D expenses ($35.2 million), and G\u0026A expenses ($9.2 million), along with business updates on clinical trial progress. The Item 2.02 classification and attached press release (Exhibit 99.1) titled \"Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates\" confirm this is a standard earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:02.084003+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-08-06"},{"id":26909,"accession_number":"0001725160-26-000061","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a Corporate Presentation (Exhibit 99.2) to be presented at investor conferences, but the substantive content is driven by Exhibit 99.1, which is a formal earnings release announcing \"Second Quarter 2026 Financial Results and Business Updates.\" The release discloses Q2 2026 financial results (R\u0026D expenses of $35.2M, G\u0026A of $9.2M, cash position of $174.6M) and material clinical/regulatory milestones (DENALI enrollment completion, FDA Type D meeting alignment, ASPENOVA Phase 3 first patient dosed). This is a classic earnings release with financial results and material business updates, even though technically filed under Item 7.01 rather than Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:02.084003+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-08-06"}]}